Navigation Links
Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia
Date:6/3/2011

CHICAGO, June 3, 2011 /PRNewswire/ -- Cornerstone Pharmaceuticals and Wake Forest Baptist Medical Center today announced key findings from a Phase I clinical trial of Cornerstone's first-in-class cancer metabolism inhibitor drug, CPI-613 in Acute Myeloid Leukemia (AML). Data will be presented at the 47th Annual meeting of American Society of Clinical Oncology (ASCO): http://www.chicago2011.asco.org/. Cornerstone is a leader in the discovery and development of cancer therapies based on the science of cancer metabolism.

CPI-613 is being studied at Wake Forest Baptist's Comprehensive Cancer Center to evaluate safety, tolerability, maximum tolerated dose, efficacy, and pharmacokinetics for patients with relapsed and refractory hematologic malignancies. The novel agent, CPI-613, has activity against several acute leukemia cell lines and may have activity in patients with relapsed disease. The mode of cytotoxicity and degree of synergy with more traditional agents remains a focus of ongoing study.

"This study is important because relatively few treatment options exist for patients with AML," said CEO Cornerstone Pharmaceuticals, Robert Shorr, Ph.D. "Preliminary results from the ongoing Phase I study demonstrate the safety of first-in-class agent, CPI-613, with very few adverse events, and support further exploration of CPI-613 as a potential treatment for AML and other hematologic malignancies."

According to the National Cancer Institute, 1 in 77 men and women will be diagnosed with leukemia during their lifetime. It is estimated that of the 43,050 Americans diagnosed annually, 21,840 of those will die of leukemia in 2011. Chemotherapy is the standard of treatment for untreated adult

SOURCE Cornerstone Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
3. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
4. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
5. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
8. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
9. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
10. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
11. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... BreedIT Corp., (OTCQB: BRDT) ... worldwide license holder and distributor of highly sophisticated ... today is pleased to announce the formation of ... a leading Israeli medical Cannabis breeder. ... breeds of medical Cannabis to meet the requests ...
(Date:8/21/2014)... PARK, N.J. , Aug. 21, 2014 /PRNewswire/ ... pharmacy group purchasing organization (GPO), is pleased to ... to collaborate on a host of innovative specialty ... help Aurora deliver enhanced therapy management services to ... Management (OTM) system. Aurora will use ...
(Date:8/21/2014)... 2014 Professional Compounding Centers of America ... awarding the three best scientific presentations at the ... . The Formulating Better Medicines for Children ... Athens, Greece , includes dozens of ... from which three winners will be selected by ...
Breaking Medicine Technology:BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2
... Nov. 5 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Trademark Office has issued a patent covering the approved ... treatment of phenylketonuria (PKU). The patent expires in ... based on the discovery that food increases the bioavailability ...
... Rochester Medical Corporation (Nasdaq: ROCM ) today announced ... 30, 2009. , The Company reported sales of $9,009,000 for ... of last year. The Company reported a quarterly net ... net income of $342,000 or $.03 per diluted share for ...
Cached Medicine Technology:United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food 2United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food 3United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food 4Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 2Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 3Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 4Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 5Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 6Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 7Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 8Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 9Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 10Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 11Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 12
(Date:8/21/2014)... Greater awareness among parents and providers of the ... full term has decreased the practice in the United ... elective deliveries (EEDs) still occur too frequently. A ... as delivery before 39 weeks without medical or obstetrical ... and offers no benefit to mothers or infants. Leading ...
(Date:8/21/2014)... Steven Reinberg HealthDay ... An experimental drug shows promise in treating respiratory syncytial virus ... "We are finally making major progress in being able ... cause of serious viral pneumonia, second only to influenza virus," ... at the University of Tennessee College of Medicine in Memphis. ...
(Date:8/21/2014)... United Benefit Advisors (UBA), the nation’s ... to announce Trinity Benefit Advisors as its newest ... Benefit Advisors is a full service firm that ... Their consultative approach is comprised of four components: ... monitoring. Their dedication to effective results and absolute ...
(Date:8/21/2014)... stem cells (MSCs) are present in virtually every type ... after injury. But the theory that MSCs are released ... organ damage, and migrate to the site of injury, ... conclusive evidence to resolve the controversy over the mobilization ... study published in Stem Cells and Development , ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... American Corporate Health, was recently recognized as ... professionals in the field of workers’ compensation. ... Workers’ Compensation and Occupational Medicine Conference was ... attorneys, physicians, nurses, case managers, disability specialists, ...
Breaking Medicine News(10 mins):Health News:New “Playbook” Aims to Eliminate Early Elective Deliveries in the United States 2Health News:New “Playbook” Aims to Eliminate Early Elective Deliveries in the United States 3Health News:New Drug May Fight Serious Respiratory Virus in Infants 2Health News:New Drug May Fight Serious Respiratory Virus in Infants 3Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 2Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 3Health News:Dr. Vasili Gatsinaris Named One of the Top 50 Most Influential in Workers’ Compensation 2
... of problems right away, study notes , THURSDAY, July 16 ... soldiers from the Iraq and Afghanistan wars seen at VA ... a new study shows. , Curiously, the researchers from the ... diagnoses were not made in the first year that a ...
... Cardinals, Wide-Receiver and Pro Bowl MVP Larry Fitzgerald Encourages Parents to Take Action ... The College of Optometrists in Vision Development (COVD) ... take to ensure their children aren,t struggling with reading and learning because of ... , "The public doesn,t realize that you need over 15 visual ...
... , White Paper Details "Unforeseen Benefits" of ... WASHINGTON, July 16 Treating Americans who are addicted to alcohol and ... over a decade, according to an analysis released today by the Closing ... The white paper, "Unforeseen Benefits: Addiction Treatment Reduces Health Care Costs," ...
... major form of the disease , THURSDAY, July 16 ... with a stray genetic process critical in the development and ... strategy, described by researchers from the University of Rochester in ... symptoms of the debilitating disease and even, in some cases, ...
... Governor Walker to join University of ... , SAN JOSE, Calif., July 16 Olene Walker has ... interview later this month will likely be the most compelling from the former Utah ... be sharing her personal struggle with a fatal lung disease. , ...
... Archer: "We,re Determined to Make the House Bill ... " , , WASHINGTON, July ... Archer today praised the House for introducing a health reform bill that delivers ... is designed to control costs and deliver quality affordable health care to all. She ...
Cached Medicine News:Health News:Many Veterans Need Mental Health Care 2Health News:Many Veterans Need Mental Health Care 3Health News:Many Veterans Need Mental Health Care 4Health News:Does Your Child Need Vision Therapy? 2Health News:Does Your Child Need Vision Therapy? 3Health News:Does Your Child Need Vision Therapy? 4Health News:Addiction Treatment Will Help Make Health Reform Affordable, New Analysis Shows 2Health News:Addiction Treatment Will Help Make Health Reform Affordable, New Analysis Shows 3Health News:Scientists Reverse Muscular Dystrophy in Mice 2Health News:Scientists Reverse Muscular Dystrophy in Mice 3Health News:Former Utah Governor to Talk About Her Battle With PF on ABC 4 Salt Lake City, July 22nd 2Health News:Former Utah Governor to Talk About Her Battle With PF on ABC 4 Salt Lake City, July 22nd 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: